Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 5-((1-methyl-3-indolyl)carbonyl)-4,5,6,7-tetrahydro-1h-benzimidazol
2. Methanone, (1-methyl-1h-indol-3-yl)(4,5,6,7-tetrahydro-1h-benzimidazol-5-yl)-, Monohydrochloride, (r)-
3. Nasea
4. Ramosetron Hydrochloride
5. Ym 060
6. Ym-060
7. Ym060
1. 132036-88-5
2. Ramosetron [inn]
3. (1-methylindol-3-yl)-[(5r)-4,5,6,7-tetrahydro-3h-benzimidazol-5-yl]methanone
4. 7zro0sc54y
5. Chembl1643895
6. Ramosetron (inn)
7. (r)-(1-methyl-1h-indol-3-yl)(4,5,6,7-tetrahydro-1h-benzo[d]imidazol-6-yl)methanone
8. Unii-7zro0sc54y
9. Nor-ym 060
10. Ramosetron [mi]
11. Ramosetron [who-dd]
12. Schembl16701
13. Gtpl2301
14. Dtxsid0043842
15. Chebi:135156
16. Zinc5116719
17. Bdbm50334454
18. (-)-(r)-1-methylindol-3-yl 4,5,6,7-tetrahydro-5-benzimidazolylketone
19. Akos015896003
20. Db09290
21. R-146
22. D08466
23. A806353
24. Ar-270/43507766
25. Q2979523
26. (-)-(r)-1-methylindol-3-yl-4,5,6,7-tetrahydro-5-benzimidazolyl Ketone
27. (-)-(r)-1-methylindol-3-yl-4,5,6,7-tetrahydro-5-benzimidazolyl Ketone.
28. (1-methyl-1h-indol-3-yl)(4,5,6,7-tetrahydro-1h-benzimidazol-6-yl)methanone
29. (1-methylindol-3-yl)-[(5r)-4,5,6,7-tetrahydro-3h-benzimidazol-5-yl]methanone.
30. (r)-(-)-5-[(1-methyl-3-indolyl)carbonyl]-4,5,6,7-tetrahydrobenzimidazole
31. (r)-5-[(1-methylindole-3-yl)carbonyl]-4,5,6,7-tetrahydro-1h-bezimidazole
32. Methanone, (1-methyl-1h-indol-3-yl)[(6r)-4,5,6,7-tetrahydro-1h-benzimidazol-6-yl]-
33. Methanone,(1-methyl-1h-indol-3-yl)[(6r)-4,5,6,7-tetrahydro-1h-benzimidazol-6-yl]-
Molecular Weight | 279.34 g/mol |
---|---|
Molecular Formula | C17H17N3O |
XLogP3 | 2.2 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 2 |
Exact Mass | 279.137162174 g/mol |
Monoisotopic Mass | 279.137162174 g/mol |
Topological Polar Surface Area | 50.7 Ų |
Heavy Atom Count | 21 |
Formal Charge | 0 |
Complexity | 413 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
For the treatment of nausea and vomiting and diarrhea-predominant irritable bowel syndrome in males.
Serotonin Antagonists
Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. (See all compounds classified as Serotonin Antagonists.)
Antiemetics
Drugs used to prevent NAUSEA or VOMITING. (See all compounds classified as Antiemetics.)
Registration Number : 226MF10230
Registrant's Address : Via San Faustino, 68 20134 Milano-Italy
Initial Date of Registration : 2014-12-08
Latest Date of Registration :
Registration Number : 221MF10177
Registrant's Address : Via San Faustino, 68 20134 Milano-Italy
Initial Date of Registration : 2009-08-07
Latest Date of Registration :
Registration Number : 221MF10177
Registrant's Address : Via San Faustino, 68 20134 Milano-Italy
Initial Date of Registration : 2009-08-07
Latest Date of Registration : 2009-08-07
Registration Number : 226MF10230
Registrant's Address : Via San Faustino, 68 20134 Milano-Italy
Initial Date of Registration : 2014-12-08
Latest Date of Registration : 2014-12-08
About the Company : We, Hana Pharmaceutical Co., Ltd. was founded the name of Woo-Chun Pharmaceutical Company in 1958. We also changed our company name to Hana in 1996. Our aim to support people can ...
About the Company : Alchemia is dedicated to the production of high-quality active ingredients and intermediates for the pharmaceutical industry. Our goal is to offer products manufactured to the hig...
About the Company : Polaris AI Pharma is a dynamic company specializing in innovative pharmaceutical solutions. Leveraging cutting-edge AI technology, it focuses on drug discovery, development, and op...
About the Company : Refarmed Chemicals is a fully integrated Swiss-based marketing company with extensive experience in the generics industry. Our global market activity and strategic offices located ...
Details:
Undisclosed
Lead Product(s): Ramosetron,Aprepitant,Dexamethasone
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Other Small Molecule
Sponsor: Catholic University of Korea | Astellas Pharma
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 26, 2015
Lead Product(s) : Ramosetron,Aprepitant,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Catholic University of Korea | Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 26, 2015
Details:
Undisclosed
Lead Product(s): Ramosetron,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 06, 2013
Lead Product(s) : Ramosetron,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 06, 2013
Details:
Undisclosed
Lead Product(s): Ramosetron,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 29, 2012
Lead Product(s) : Ramosetron,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 29, 2012
Details:
Undisclosed
Lead Product(s): Ramosetron,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Korean Cancer Study Group | Astellas Pharma
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 22, 2012
Lead Product(s) : Ramosetron,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Korean Cancer Study Group | Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 22, 2012
Details:
Undisclosed
Lead Product(s): Ramosetron,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 14, 2011
Lead Product(s) : Ramosetron,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 14, 2011
Details:
Undisclosed
Lead Product(s): Ramosetron,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 13, 2011
Lead Product(s) : Ramosetron,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 13, 2011
Details:
Undisclosed
Lead Product(s): Ramosetron,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 11, 2011
Lead Product(s) : Ramosetron,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 11, 2011
Details:
Undisclosed
Lead Product(s): Ramosetron,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 20, 2010
Lead Product(s) : Ramosetron,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 20, 2010
Details:
Undisclosed
Lead Product(s): Ramosetron,Aprepitant,Dexamethasone
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Merck & Co
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 12, 2010
Lead Product(s) : Ramosetron,Aprepitant,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Ramosetron, Aprepitant and Dexamethasone (RAD) in Solid Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 12, 2010
4,5,6,7-tetrahydro-1H-benzo[d]imidazole-5-carboxyl...
CAS Number : 131020-57-0
End Use API : Ramosetron
About The Company : Polaris AI Pharma is a dynamic company specializing in innovative pharmaceutical solutions. Leveraging cutting-edge AI technology, it focuses on drug discovery,...
4,5,6,7-Tetrahydro-1H-Benzoimidazole-5-Carboxylic ...
CAS Number : 131020-57-0
End Use API : Ramosetron
About The Company : Suraj Laboratories Private Limited, established in 2021, is a pharmaceutical firm providing Contract Research and Manufacturing Services (CRAMS), Custom Synthes...
Regulatory Info : Generic
Registration Country : India
Brand Name :
Dosage Form : Tablet
Dosage Strength : 0.1MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : India
Market Place
ABOUT THIS PAGE
100
PharmaCompass offers a list of Ramosetron API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ramosetron manufacturer or Ramosetron supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ramosetron manufacturer or Ramosetron supplier.
PharmaCompass also assists you with knowing the Ramosetron API Price utilized in the formulation of products. Ramosetron API Price is not always fixed or binding as the Ramosetron Price is obtained through a variety of data sources. The Ramosetron Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Ramosetron manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ramosetron, including repackagers and relabelers. The FDA regulates Ramosetron manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ramosetron API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ramosetron manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Ramosetron supplier is an individual or a company that provides Ramosetron active pharmaceutical ingredient (API) or Ramosetron finished formulations upon request. The Ramosetron suppliers may include Ramosetron API manufacturers, exporters, distributors and traders.
click here to find a list of Ramosetron suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Ramosetron Drug Master File in Japan (Ramosetron JDMF) empowers Ramosetron API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Ramosetron JDMF during the approval evaluation for pharmaceutical products. At the time of Ramosetron JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Ramosetron suppliers with JDMF on PharmaCompass.
Ramosetron Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ramosetron GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ramosetron GMP manufacturer or Ramosetron GMP API supplier for your needs.
A Ramosetron CoA (Certificate of Analysis) is a formal document that attests to Ramosetron's compliance with Ramosetron specifications and serves as a tool for batch-level quality control.
Ramosetron CoA mostly includes findings from lab analyses of a specific batch. For each Ramosetron CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ramosetron may be tested according to a variety of international standards, such as European Pharmacopoeia (Ramosetron EP), Ramosetron JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ramosetron USP).